Abstract
To summarize the available evidence regarding antifungal dosing in obese adults as well as to provide meaningful guidance on the dosing of each antifungal agent in obese patients. The pharmacokinetic evidence regarding dosing antifungal agents in obesity is limited. Fluconazole’s volume of distribution (VD) is influenced by BMI. Therapeutic drug monitoring (TDM) studies provide some insights into dosing voriconazole in obesity, but not with posaconazole. Isavuconazole seems to be unaffected by weight. The available data for echinocandins suggests that increased doses are likely necessary in obese patients. TDM may be beneficial, particularly for azoles when available in a timely manner. Fluconazole and voriconazole dosing should be based on total body weight and adjusted body weight, respectively. Posaconazole may have reduced exposures in obese patients, but data on its new dosage forms is lacking. Isavuconazole appears unaffected by weight. Echinocandin doses likely need to be increased in obese patients, but the exact weight and dosages remain elusive.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
